BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 842,771 shares of the medical equipment provider’s stock after purchasing an additional 18,473 shares during the quarter. Geode Capital Management LLC’s holdings in BioLife Solutions were worth $21,107,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BLFS. Barclays PLC grew its holdings in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after purchasing an additional 10,803 shares during the last quarter. State Street Corp grew its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Stifel Financial Corp raised its position in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of BioLife Solutions in the third quarter valued at about $28,000. Finally, Rockefeller Capital Management L.P. grew its position in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after purchasing an additional 262,504 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BLFS has been the subject of several research reports. HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Benchmark restated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum lifted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $26.59 on Friday. The company has a market cap of $1.23 billion, a P/E ratio of -25.08 and a beta of 1.91. The business has a fifty day simple moving average of $25.28 and a 200-day simple moving average of $23.91. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Insiders Place Their Bets

In other BioLife Solutions news, EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the transaction, the executive vice president now owns 302,046 shares of the company’s stock, valued at $6,394,313.82. This trade represents a 7.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 64,259 shares of company stock valued at $1,424,708. Insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.